Summary of Key Points
Recently, pharmaceutical companies such as Novo Nordisk, Eli Lilly, and Roche presented clinical data for their new generation of weight loss drugs at the International Diabetes Association (ADA) conference, indicating a shift in the competitive focus from “who can lose the most weight” to “who can lose the weight in the best way.” These new drugs have made breakthroughs in four areas: dual-targeting to reduce side effects, fat reduction while preserving muscle to prevent rebound, extreme weight loss approaching surgical results, and oral small molecules for increased convenience, allowing for differentiated competition based on the needs of different patients, rather than simply comparing the degree of weight loss.
Detailed Analysis
1. Dual-Targeting Drugs: Less Nausea, More Comfortable Weight Loss
Many people who use GLP-1 class weight loss injections (such as semaglutide) experience nausea and diarrhea, which sometimes leads to discontinuation of the medication. Novo Nordisk and Roche have developed “dual-targeting” drugs that activate both GLP-1 and glucagon-like peptide-1 (GLP-1) receptors, controlling appetite while reducing gastrointestinal side effects.
- Novo Nordisk’s Zenagamtide: Achieved a 14.6% weight loss after 36 weeks, with significant improvements in blood sugar control (HbA1c reduced by 1.71%). The key benefit is that fewer patients experienced nausea and vomiting compared to single-targeting drugs, making it easier for them to continue treatment.
- Roche’s Petrelintide: Led to a 10.7% weight loss after 42 weeks, with gastrointestinal side effects similar to those of a placebo, and only 1.5% of patients discontinued the drug due to discomfort.
In simple terms: While previous weight loss medications were often uncomfortable, these new drugs make the process less painful and more sustainable.
2. Fat Reduction While Preserving Muscle: Losing Only Fat, Not Muscle
Conventional weight loss methods (including GLP-1 monotherapies) can result in the loss of both fat and muscle, which slows metabolism and increases the risk of rebound. Eli Lilly’s combination of Bimagrumab and semaglutide addresses this issue:
- Effect: Achieved a 22.1% weight loss after 72 weeks, with 92% of that being fat loss and only 2.9% muscle loss (compared to 7.4% muscle loss with semaglutide alone); visceral fat (fat in the abdomen) was reduced by 58.2%, which is more than 20% greater than with a single drug.
- Suitable for: Middle-aged and older adults who are concerned about muscle loss leading to instability, or those who want to maintain their weight long-term without rebound.
In simple terms: Previous weight loss methods resulted in overall weight loss, including muscle. These new drugs target fat specifically, preserving muscle and reducing the risk of rebound, resulting in a fitter body.
3. Triple-Targeting Drugs: Weight Loss Effects Comparable to Surgery, Suitable for Severe Obesity
Eli Lilly’s Retatrutide is currently the most potent weight loss drug, activating three metabolic pathways (GLP-1, GIP, and glucagon). The results are impressive:
- Data: Achieved a 28.3% weight loss after 80 weeks, with nearly half of the participants losing more than 30% of their initial weight (e.g., a 60-pound reduction for a 200-pound person), and over a quarter losing more than 35%. The effects are comparable to those of gastric bypass surgery.
- Additional Benefits: Can also improve knee arthritis pain and sleep apnea (common in overweight individuals).
In simple terms: For extremely obese individuals (e.g., 300 pounds) with diabetes or respiratory issues, these drugs can achieve surgical-level weight loss without the risks associated with surgery.
4. Oral Small Molecules: As Convenient as Taking Cold Medicine, with Better Results
Previous oral GLP-1 medications (such as semaglutide) required fasting and limited water intake, which was inconvenient. Eli Lilly’s Orforglipron is a small molecule oral drug that solves these issues:
- Convenience: One tablet per day, no need for fasting or water restrictions, similar to taking a common cold medicine.
- Effect: Led to nearly 4 kilograms more weight loss compared to semaglutide, with improved blood sugar control (HbA1c reduced by 0.8%). It also helps maintain the weight loss achieved with injections; for example, after using tirzepatide, 74.7% of the weight loss was maintained with Orforglipron, compared to only 49.2% with a placebo.
In simple terms: For those who dislike injections or find the process cumbersome, this is a convenient and effective alternative that eliminates the need for weekly injections and dietary adjustments.
Conclusion: Weight Loss Drugs Entering an Era of Precision
Modern weight loss drugs no longer focus on who can lose the most weight, but on meeting individual needs:
- Those concerned about side effects should choose dual-targeting drugs.
- Those worried about rebound or muscle loss should opt for fat reduction while preserving muscle combinations.
- Severe obese individuals seeking rapid weight loss should consider triple-targeting drugs.
- Those looking for convenience should choose oral small molecule medications.
This shift towards personalized solutions means that weight loss is no longer a painful experience but is more tailored to each person’s lifestyle, making it healthier and more sustainable. This marks the maturity of weight loss drug development.